Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2000-02-03

AUTHORS

U Halm, T Schumann, I Schiefke, H Witzigmann, J Mössner, V Keim

ABSTRACT

Chemotherapy with gemcitabine has been shown to be an effective regimen in advanced or metastatic pancreatic cancer with improvement of both quality of life and survival time. The response of the tumour marker CA 19–9 to chemotherapy with gemcitabine was studied in order to find out whether it is related to survival time of patients. Forty-three consecutive patients (median age 61 years, range 39–76 years; 20 males, 23 females) suffering from histologically proven locally advanced or metastatic pancreatic adenocarcinoma and a baseline Karnofsky-index ≥ 60 were treated with gemcitabine in a dose of 1000 mg m−2weekly × 7 followed by 1 week of rest during the first cycle and thereafter 1000 mg m−2weekly × 3 followed by 1 week of rest until progression. In 36 of 43 patients serial measurements of CA 19–9 could be performed. Patients with a decrease of > 20% of the baseline CA 19–9 level after 8 weeks of treatment (n = 25) had a significantly better median survival than patients with a rise or a decrease ≤ 20% (n = 11) (268 vs 110 days;P< 0.001). The response of CA 19–9 was the strongest independent predictor of survival (P< 0.001) in the multivariate analysis. In conclusion, a decrease of CA 19–9 > 20% during the first weeks of chemotherapy with gemcitabine is associated with a better survival of patients with locally advanced or metastatic pancreatic cancer. Serial measurements of CA 19–9 are useful to decide whether further chemotherapy after the first weeks of treatment is indicated. © 2000 Cancer Research Campaign More... »

PAGES

1013-1016

Identifiers

URI

http://scigraph.springernature.com/pub.10.1054/bjoc.1999.1035

DOI

http://dx.doi.org/10.1054/bjoc.1999.1035

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1003281603

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10737382


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Age Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CA-19-9 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sex Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine II, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine II, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Halm", 
        "givenName": "U", 
        "id": "sg:person.0641775212.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641775212.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine II, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine II, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schumann", 
        "givenName": "T", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine II, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine II, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schiefke", 
        "givenName": "I", 
        "id": "sg:person.01104777015.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104777015.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery II, University of Leipzig, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany", 
          "id": "http://www.grid.ac/institutes/grid.9647.c", 
          "name": [
            "Department of Surgery II, University of Leipzig, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Witzigmann", 
        "givenName": "H", 
        "id": "sg:person.01036546622.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036546622.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine II, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine II, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "M\u00f6ssner", 
        "givenName": "J", 
        "id": "sg:person.01127636715.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127636715.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine II, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine II, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Keim", 
        "givenName": "V", 
        "id": "sg:person.01001727777.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001727777.20"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/978-1-4612-1810-4_7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016132379", 
          "https://doi.org/10.1007/978-1-4612-1810-4_7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1994.93", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037762550", 
          "https://doi.org/10.1038/bjc.1994.93"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1998.50", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014731839", 
          "https://doi.org/10.1038/bjc.1998.50"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01542654", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027172486", 
          "https://doi.org/10.1007/bf01542654"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1996.18", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011815301", 
          "https://doi.org/10.1038/bjc.1996.18"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-02-03", 
    "datePublishedReg": "2000-02-03", 
    "description": "Chemotherapy with gemcitabine has been shown to be an effective regimen in advanced or metastatic pancreatic cancer with improvement of both quality of life and survival time. The response of the tumour marker CA 19\u20139 to chemotherapy with gemcitabine was studied in order to find out whether it is related to survival time of patients. Forty-three consecutive patients (median age 61 years, range 39\u201376 years; 20 males, 23 females) suffering from histologically proven locally advanced or metastatic pancreatic adenocarcinoma and a baseline Karnofsky-index \u2265 60 were treated with gemcitabine in a dose of 1000 mg m\u22122weekly \u00d7 7 followed by 1 week of rest during the first cycle and thereafter 1000 mg m\u22122weekly \u00d7 3 followed by 1 week of rest until progression. In 36 of 43 patients serial measurements of CA 19\u20139 could be performed. Patients with a decrease of > 20% of the baseline CA 19\u20139 level after 8 weeks of treatment (n = 25) had a significantly better median survival than patients with a rise or a decrease \u2264 20% (n = 11) (268 vs 110 days;P< 0.001). The response of CA 19\u20139 was the strongest independent predictor of survival (P< 0.001) in the multivariate analysis. In conclusion, a decrease of CA 19\u20139 > 20% during the first weeks of chemotherapy with gemcitabine is associated with a better survival of patients with locally advanced or metastatic pancreatic cancer. Serial measurements of CA 19\u20139 are useful to decide whether further chemotherapy after the first weeks of treatment is indicated. \u00a9 2000 Cancer Research Campaign", 
    "genre": "article", 
    "id": "sg:pub.10.1054/bjoc.1999.1035", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "82"
      }
    ], 
    "keywords": [
      "metastatic pancreatic cancer", 
      "week of rest", 
      "CA 19", 
      "pancreatic cancer", 
      "serial measurements", 
      "survival time", 
      "tumor marker CA 19", 
      "first week", 
      "patients serial measurements", 
      "baseline CA 19", 
      "better median survival", 
      "metastatic pancreatic adenocarcinoma", 
      "weeks of treatment", 
      "strong independent predictor", 
      "quality of life", 
      "further chemotherapy", 
      "Karnofsky index", 
      "effective regimen", 
      "median survival", 
      "consecutive patients", 
      "independent predictors", 
      "pancreatic adenocarcinoma", 
      "better survival", 
      "patients", 
      "chemotherapy", 
      "gemcitabine", 
      "multivariate analysis", 
      "weeks", 
      "survival", 
      "cancer", 
      "treatment", 
      "regimen", 
      "adenocarcinoma", 
      "decrease", 
      "dose", 
      "progression", 
      "response", 
      "first cycle", 
      "rest", 
      "predictors", 
      "conclusion", 
      "levels", 
      "life", 
      "time", 
      "improvement", 
      "quality", 
      "analysis", 
      "measurements", 
      "rise", 
      "cycle", 
      "order"
    ], 
    "name": "Decrease of CA 19\u20139 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer", 
    "pagination": "1013-1016", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1003281603"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1054/bjoc.1999.1035"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10737382"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1054/bjoc.1999.1035", 
      "https://app.dimensions.ai/details/publication/pub.1003281603"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:48", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_315.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1054/bjoc.1999.1035"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1054/bjoc.1999.1035'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1054/bjoc.1999.1035'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1054/bjoc.1999.1035'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1054/bjoc.1999.1035'


 

This table displays all metadata directly associated to this object as RDF triples.

237 TRIPLES      21 PREDICATES      98 URIs      85 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1054/bjoc.1999.1035 schema:about N00e82b8efb8747aa826494265c09889d
2 N050c2608c701418fab718339a21d546a
3 N0598239bd7f84e68a8327ba568437e9b
4 N155a97f8927c4090a0fb73588e0b01e3
5 N18624b2e61694e4d94a3fd06e34ae260
6 N1c2cf143bf764172a6a0cc835a1bb9ba
7 N25ae44091fa24d6ea32d5f9476b1c5cd
8 N353d15a5ec4a46b5b421254c6870c8e2
9 N3ad1cd446e6642f9a9c603733e54f84d
10 N3c3a4c05181342b1a6ba18f9c90e0612
11 N40f874b59245459097a41c6b608edcf3
12 N51d9de3bbe3e48a0b525ca04e210bb09
13 N80c7f045189c4a97938dc23830ffa9a5
14 N83962b94bcbe49c88159856532b5c47e
15 N8909d11a2263413db190cddad612585a
16 Nb4be3ad9f1a24f3bbc2daf3433085160
17 Nef567d31ab72426f96c0c20def6b1a27
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author Nda3c68ea146a44d28b91705f5d539717
21 schema:citation sg:pub.10.1007/978-1-4612-1810-4_7
22 sg:pub.10.1007/bf01542654
23 sg:pub.10.1038/bjc.1994.93
24 sg:pub.10.1038/bjc.1996.18
25 sg:pub.10.1038/bjc.1998.50
26 schema:datePublished 2000-02-03
27 schema:datePublishedReg 2000-02-03
28 schema:description Chemotherapy with gemcitabine has been shown to be an effective regimen in advanced or metastatic pancreatic cancer with improvement of both quality of life and survival time. The response of the tumour marker CA 19–9 to chemotherapy with gemcitabine was studied in order to find out whether it is related to survival time of patients. Forty-three consecutive patients (median age 61 years, range 39–76 years; 20 males, 23 females) suffering from histologically proven locally advanced or metastatic pancreatic adenocarcinoma and a baseline Karnofsky-index ≥ 60 were treated with gemcitabine in a dose of 1000 mg m−2weekly × 7 followed by 1 week of rest during the first cycle and thereafter 1000 mg m−2weekly × 3 followed by 1 week of rest until progression. In 36 of 43 patients serial measurements of CA 19–9 could be performed. Patients with a decrease of > 20% of the baseline CA 19–9 level after 8 weeks of treatment (n = 25) had a significantly better median survival than patients with a rise or a decrease ≤ 20% (n = 11) (268 vs 110 days;P< 0.001). The response of CA 19–9 was the strongest independent predictor of survival (P< 0.001) in the multivariate analysis. In conclusion, a decrease of CA 19–9 > 20% during the first weeks of chemotherapy with gemcitabine is associated with a better survival of patients with locally advanced or metastatic pancreatic cancer. Serial measurements of CA 19–9 are useful to decide whether further chemotherapy after the first weeks of treatment is indicated. © 2000 Cancer Research Campaign
29 schema:genre article
30 schema:isAccessibleForFree true
31 schema:isPartOf Ne62eb71f7e774936b24408a913e7d6af
32 Nf20e7c8d8f6945f8a29c0657bc1bade5
33 sg:journal.1017082
34 schema:keywords CA 19
35 Karnofsky index
36 adenocarcinoma
37 analysis
38 baseline CA 19
39 better median survival
40 better survival
41 cancer
42 chemotherapy
43 conclusion
44 consecutive patients
45 cycle
46 decrease
47 dose
48 effective regimen
49 first cycle
50 first week
51 further chemotherapy
52 gemcitabine
53 improvement
54 independent predictors
55 levels
56 life
57 measurements
58 median survival
59 metastatic pancreatic adenocarcinoma
60 metastatic pancreatic cancer
61 multivariate analysis
62 order
63 pancreatic adenocarcinoma
64 pancreatic cancer
65 patients
66 patients serial measurements
67 predictors
68 progression
69 quality
70 quality of life
71 regimen
72 response
73 rest
74 rise
75 serial measurements
76 strong independent predictor
77 survival
78 survival time
79 time
80 treatment
81 tumor marker CA 19
82 week of rest
83 weeks
84 weeks of treatment
85 schema:name Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
86 schema:pagination 1013-1016
87 schema:productId N0099b47787a84fdfa583d5c60a4ea193
88 Nbb1019c2a78043c3b620d3a2aef850d1
89 Ndf07734586604e19982e569c85e1711f
90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003281603
91 https://doi.org/10.1054/bjoc.1999.1035
92 schema:sdDatePublished 2022-09-02T15:48
93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
94 schema:sdPublisher Nc1e0915e8fc14e5eb39c70688a887498
95 schema:url https://doi.org/10.1054/bjoc.1999.1035
96 sgo:license sg:explorer/license/
97 sgo:sdDataset articles
98 rdf:type schema:ScholarlyArticle
99 N0099b47787a84fdfa583d5c60a4ea193 schema:name pubmed_id
100 schema:value 10737382
101 rdf:type schema:PropertyValue
102 N00e82b8efb8747aa826494265c09889d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Prospective Studies
104 rdf:type schema:DefinedTerm
105 N050c2608c701418fab718339a21d546a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Middle Aged
107 rdf:type schema:DefinedTerm
108 N0598239bd7f84e68a8327ba568437e9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Humans
110 rdf:type schema:DefinedTerm
111 N155a97f8927c4090a0fb73588e0b01e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Time Factors
113 rdf:type schema:DefinedTerm
114 N18624b2e61694e4d94a3fd06e34ae260 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Sex Factors
116 rdf:type schema:DefinedTerm
117 N1c2cf143bf764172a6a0cc835a1bb9ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Aged
119 rdf:type schema:DefinedTerm
120 N25ae44091fa24d6ea32d5f9476b1c5cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Survival Analysis
122 rdf:type schema:DefinedTerm
123 N353d15a5ec4a46b5b421254c6870c8e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Pancreatic Neoplasms
125 rdf:type schema:DefinedTerm
126 N3ad1cd446e6642f9a9c603733e54f84d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Antimetabolites, Antineoplastic
128 rdf:type schema:DefinedTerm
129 N3c3a4c05181342b1a6ba18f9c90e0612 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Biomarkers, Tumor
131 rdf:type schema:DefinedTerm
132 N40f874b59245459097a41c6b608edcf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name CA-19-9 Antigen
134 rdf:type schema:DefinedTerm
135 N51d9de3bbe3e48a0b525ca04e210bb09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Adult
137 rdf:type schema:DefinedTerm
138 N749d4ed14e1f40f7b07ea0f82d5f03c6 rdf:first sg:person.01001727777.20
139 rdf:rest rdf:nil
140 N7dcf77b01d594685bbf846bd1d74ce12 rdf:first sg:person.01127636715.31
141 rdf:rest N749d4ed14e1f40f7b07ea0f82d5f03c6
142 N80c7f045189c4a97938dc23830ffa9a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Male
144 rdf:type schema:DefinedTerm
145 N82c1cc5c6db54688ace574c7e561fcb9 schema:affiliation grid-institutes:None
146 schema:familyName Schumann
147 schema:givenName T
148 rdf:type schema:Person
149 N83962b94bcbe49c88159856532b5c47e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Age Factors
151 rdf:type schema:DefinedTerm
152 N8909d11a2263413db190cddad612585a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Prognosis
154 rdf:type schema:DefinedTerm
155 N9dba484b6cbe4812a6b66dae9a29381b rdf:first sg:person.01036546622.28
156 rdf:rest N7dcf77b01d594685bbf846bd1d74ce12
157 Nb347909c253346b2a5e128dda224f8ab rdf:first N82c1cc5c6db54688ace574c7e561fcb9
158 rdf:rest Ne3731c528a1f4953926d593c7699ed9a
159 Nb4be3ad9f1a24f3bbc2daf3433085160 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Deoxycytidine
161 rdf:type schema:DefinedTerm
162 Nbb1019c2a78043c3b620d3a2aef850d1 schema:name doi
163 schema:value 10.1054/bjoc.1999.1035
164 rdf:type schema:PropertyValue
165 Nc1e0915e8fc14e5eb39c70688a887498 schema:name Springer Nature - SN SciGraph project
166 rdf:type schema:Organization
167 Nda3c68ea146a44d28b91705f5d539717 rdf:first sg:person.0641775212.05
168 rdf:rest Nb347909c253346b2a5e128dda224f8ab
169 Ndf07734586604e19982e569c85e1711f schema:name dimensions_id
170 schema:value pub.1003281603
171 rdf:type schema:PropertyValue
172 Ne3731c528a1f4953926d593c7699ed9a rdf:first sg:person.01104777015.13
173 rdf:rest N9dba484b6cbe4812a6b66dae9a29381b
174 Ne62eb71f7e774936b24408a913e7d6af schema:issueNumber 5
175 rdf:type schema:PublicationIssue
176 Nef567d31ab72426f96c0c20def6b1a27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Female
178 rdf:type schema:DefinedTerm
179 Nf20e7c8d8f6945f8a29c0657bc1bade5 schema:volumeNumber 82
180 rdf:type schema:PublicationVolume
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
185 schema:name Oncology and Carcinogenesis
186 rdf:type schema:DefinedTerm
187 sg:journal.1017082 schema:issn 0007-0920
188 1532-1827
189 schema:name British Journal of Cancer
190 schema:publisher Springer Nature
191 rdf:type schema:Periodical
192 sg:person.01001727777.20 schema:affiliation grid-institutes:None
193 schema:familyName Keim
194 schema:givenName V
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001727777.20
196 rdf:type schema:Person
197 sg:person.01036546622.28 schema:affiliation grid-institutes:grid.9647.c
198 schema:familyName Witzigmann
199 schema:givenName H
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036546622.28
201 rdf:type schema:Person
202 sg:person.01104777015.13 schema:affiliation grid-institutes:None
203 schema:familyName Schiefke
204 schema:givenName I
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104777015.13
206 rdf:type schema:Person
207 sg:person.01127636715.31 schema:affiliation grid-institutes:None
208 schema:familyName Mössner
209 schema:givenName J
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127636715.31
211 rdf:type schema:Person
212 sg:person.0641775212.05 schema:affiliation grid-institutes:None
213 schema:familyName Halm
214 schema:givenName U
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641775212.05
216 rdf:type schema:Person
217 sg:pub.10.1007/978-1-4612-1810-4_7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016132379
218 https://doi.org/10.1007/978-1-4612-1810-4_7
219 rdf:type schema:CreativeWork
220 sg:pub.10.1007/bf01542654 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027172486
221 https://doi.org/10.1007/bf01542654
222 rdf:type schema:CreativeWork
223 sg:pub.10.1038/bjc.1994.93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037762550
224 https://doi.org/10.1038/bjc.1994.93
225 rdf:type schema:CreativeWork
226 sg:pub.10.1038/bjc.1996.18 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011815301
227 https://doi.org/10.1038/bjc.1996.18
228 rdf:type schema:CreativeWork
229 sg:pub.10.1038/bjc.1998.50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014731839
230 https://doi.org/10.1038/bjc.1998.50
231 rdf:type schema:CreativeWork
232 grid-institutes:None schema:alternateName Department of Internal Medicine II, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany
233 schema:name Department of Internal Medicine II, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany
234 rdf:type schema:Organization
235 grid-institutes:grid.9647.c schema:alternateName Department of Surgery II, University of Leipzig, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany
236 schema:name Department of Surgery II, University of Leipzig, Philipp-Rosenthal-Strasse 27, D-04103, Leipzig, Germany
237 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...